Business
Plus Therapeutics Provides Business Update on CNSide Diagnostics Subsidiary
U.S. commercial rollout of novel diagnostic platform to begin second half 2025 Underserved CNS cancer diagnostic U.S. market opportunity estimated to be in excess of $6 billion Management to host a conference call today at 9am ET HOUSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will provide a
About this update from Plus Therapeutics, Inc.
[{"type":"image","alt":"Plus Therapeutics Inc.","displaySize":"","headline":null,"caption":"Plus Therapeutics Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":172,"url":"https://media.zenfs.com/en/globenewswire.com/1d6738db871d52da7de4b5de8e51921c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iUBJ3sPkI4ud4lMmyJb.Bg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTI0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/1d6738db871d52da7de4b5de8e51921c","width":300,"height":172}},"lazy":false},{"type":"text","content":"U.S. commercial rollout of novel diagnostic platform to begin second half 2025","length":78,"tagName":"p"},{"type":"text","content":"Underserved CNS cancer diagnostic U.S. market opportunity estimated to be in excess of $6 billion","length":97,"tagName":"p"},{"type":"text","content":"Management to host a conference call today at 9am ET ","length":52,"tagName":"p"},{"type":"text","content":"HOUSTON, June 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers, will provide a business update for its wholly-owned subsidiary, CNSide Diagnostics, LLC (“CNSide”). The proprietary CNSide Cerebrospinal Fluid (CSF) Assay Platform is designed and intended for patients suspected of having central nervous system cancer metastases (CNS Mets). The first test to be commercialized, CNSide CSF Tumor Cell Enumeration (TCE), has a total addressable market estimated to be $6 billion in the U.S.1","length":683,"tagName":"p"},{"type":"text","content":"“The developer of the CNSide technology invested over $300 million in this core technology and after a year of detailed analysis and preparation by our team and key consultants, our enthusiasm regarding the unmet clinical need and the inherent value of CNSide has only grown,” said Marc H. Hedrick, M.D., Plus Therapeutics’ President and Chief Executive Officer. “CNSide, as a laboratory-developed test widely adopted under a prior commercial program, will begin to hit the market this year under our full commercial access strategy, providing Plus with an expedited path to both revenue and corporate profitability while allowing us to continue the progress in our core CNS radiotherapeutics clinical ...